What is the recommended antiresorptive therapy algorithm for osteoporosis, including first‑line oral alendronate with calcium and vitamin D, alternatives for intolerance, use of denosumab, and indications for initiating anabolic agents?

Antiresorptive Therapy Algorithm for Osteoporosis

Oral bisphosphonates (specifically alendronate or risedronate) are the first-line antiresorptive therapy for osteoporosis, strongly recommended over calcium and vitamin D alone for patients at moderate-to-high fracture risk, based on proven antifracture efficacy, safety profile, and cost-effectiveness. 1, 2, 3

Foundation: Universal Recommendations

All patients receiving osteoporosis treatment should optimize:

• Calcium intake: 1,000–1,200 mg/day (dietary plus supplemental) 1
• Vitamin D intake: 600–800 IU/day, targeting serum levels ≥20 ng/ml 1
• Lifestyle modifications: Weight-bearing or resistance training exercise, smoking cessation, limiting alcohol to 1–2 drinks/day, maintaining recommended body weight 4

Risk Stratification Framework

Adults ≥40 Years

Very High Risk: Prior osteoporotic fracture(s), BMD T-score ≤-3.5, FRAX 10-year major osteoporotic fracture (MOF) risk ≥30% or hip ≥4.5%, high-dose glucocorticoids (≥30 mg/day for >30 days or cumulative ≥5 g/year) 3, 2

High Risk: BMD T-score ≤-2.5 but >-3.5, FRAX 10-year MOF risk ≥20% but <30% or hip ≥3% but <4.5% 3, 2

Moderate Risk: FRAX 10-year MOF risk ≥10% and <20%, hip >1% and <3%, or BMD T-score between -1 and -2.4 3, 2

Adults <40 Years

Very High Risk: Prior fracture(s), glucocorticoids ≥30 mg/day, or cumulative ≥5 g/year 3, 2

Moderate Risk: Continuing glucocorticoids ≥7.5 mg/day for ≥6 months AND BMD z-score <-3 OR significant BMD loss 3, 2

Treatment Algorithm by Risk Level

Very High Fracture Risk (Adults ≥40 Years)

First-Line: Anabolic agents (teriparatide, abaloparatide, or romosozumab) are conditionally recommended over antiresorptive agents 2, 3. The 2023 ACR guideline represents an evolution from the 2017 guideline, which prioritized oral bisphosphonates even in high-risk patients 1, 4.

Alternative if anabolics contraindicated/not tolerated:

1. Oral bisphosphonates (alendronate, risedronate) - strongly recommended 2, 3
2. IV bisphosphonates (zoledronic acid, ibandronate) - conditionally recommended, higher risk profile for IV infusion 1, 4
3. Denosumab - conditionally recommended over oral/IV bisphosphonates 2, 3
4. Romosozumab - conditionally recommended but with caution due to uncertain cardiovascular harms (increased MI, stroke, death) 3, 2

Critical caveat: Sequential therapy is mandatory after anabolic agents or denosumab to prevent rebound bone loss and vertebral fractures 2, 3. After 12 months of romosozumab or 18-24 months of teriparatide/abaloparatide, transition to bisphosphonate or denosumab 5, 6.

High Fracture Risk (Adults ≥40 Years)

First-Line: Oral bisphosphonates strongly recommended over calcium and vitamin D alone 1, 4

Alternative if oral bisphosphonates not appropriate:

1. Denosumab or PTH/PTHrP - conditionally recommended over bisphosphonates 2, 3
2. IV bisphosphonates - higher risk profile than oral 1, 4
3. Romosozumab - conditionally recommended with cardiovascular caution 3, 2
4. Raloxifene (postmenopausal women only, if none of above appropriate) - limited data on hip fracture reduction, clotting risks 1, 4, 1

Moderate Fracture Risk (Adults ≥40 Years)

Conditional recommendation for oral bisphosphonates, IV bisphosphonates, denosumab, or PTH/PTHrP in no preferred order among these agents 2, 3, 2. The choice depends on:

• Patient comorbidities (e.g., renal impairment favors denosumab) 7
• Adherence concerns (oral vs. IV vs. subcutaneous administration)
• Cost considerations
• Patient preference after shared decision-making 2

Adults <40 Years

Moderate-to-Very High Risk: Oral bisphosphonates conditionally recommended over calcium and vitamin D alone 1, 4, 1

If oral bisphosphonates not appropriate, in order of preference:

1. IV bisphosphonates 1, 4
2. Teriparatide (cost and daily injection burden) 1, 4
3. Denosumab (lack of safety data with immunosuppressive agents) 1, 4

Use caution with bisphosphonates in patients who may become pregnant due to higher teratogenic risk 3, 2

Low Risk (<40 years): Optimize calcium, vitamin D, and lifestyle modifications over pharmacologic treatment 1, 4, 1

Specific Clinical Scenarios

Oral Bisphosphonate Intolerance

When oral bisphosphonates are not appropriate due to:

• GI contraindications (esophageal disorders, inability to remain upright 30 minutes) 8
• Patient preference or adherence concerns 4
• Comorbidities 4

Proceed sequentially:

1. IV bisphosphonates (zoledronic acid preferred for annual dosing) 1, 4
2. Denosumab 60 mg subcutaneous every 6 months 1, 4
3. Teriparatide (if very high risk) 1, 4

Denosumab Use

Indications: Preferred in renal impairment (creatinine clearance <60 ml/min), particularly in multiple myeloma 7. Conditionally recommended over bisphosphonates in high fracture risk 2, 3.

Critical management requirement: Must administer every 4 weeks in cancer patients or every 6 months in osteoporosis 7. Extending intervals beyond recommended frequency cannot be recommended 7. If denosumab discontinued for >6 months, bisphosphonate treatment is recommended to suppress rebound osteolysis and prevent vertebral fractures 7, 6.

Dental precautions: Patients should have dental evaluation and complete invasive dental treatments before initiating denosumab or bisphosphonates 7. Maintain adequate calcium and vitamin D throughout treatment 7.

Glucocorticoid-Induced Osteoporosis (GIOP)

The 2023 ACR guideline provides updated recommendations from the 2017 version:

Assessment: Fracture risk assessment should occur as soon as possible within 6 months of initiating ≥2.5 mg/day prednisone for >3 months, including FRAX (if ≥40 years), BMD with vertebral fracture assessment (VFA) or spine x-rays 2, 3

FRAX adjustment for glucocorticoids: If dose >7.5 mg/day, multiply 10-year MOF risk by 1.15 and hip fracture risk by 1.2 3, 2

Treatment follows same algorithm as above based on risk stratification 2, 3

Sequential Therapy Considerations

After bisphosphonates: Transitioning to zoledronic acid or denosumab shows further BMD improvements 5. However, prior bisphosphonate use may reduce BMD response to subsequent teriparatide, though anti-fracture efficacy appears preserved 5.

After denosumab: Transitioning to teriparatide is problematic due to increased bone resorption after stopping denosumab 5. Always transition to bisphosphonate or continue denosumab 6.

After anabolic agents: Antiresorptive treatment (bisphosphonates or denosumab) is mandatory and integral to maintaining anti-fracture benefits 5, 6.

Monitoring

During treatment: BMD with VFA or spinal x-ray every 1–2 years 3, 2. The 2017 ACP guideline controversially recommended against routine BMD monitoring during treatment 9, but the 2023 ACR guideline supports regular monitoring to assess treatment response and identify management issues 2, 3.

Bisphosphonate de-escalation: Most patients on zoledronate can safely de-escalate to every 12 weeks after monthly treatment for 3-6 months 7. Consider interrupting bisphosphonate therapy after 2 years in multiple myeloma patients in remission 7.

Common Pitfalls

• Failing to plan sequential therapy: Denosumab, romosozumab, and PTH/PTHrP require subsequent antiresorptive treatment; this is not optional 2, 3, 6
• Abrupt denosumab discontinuation: Results in rapid BMD decline and increased vertebral fracture risk 7, 5
• Ignoring renal function: Denosumab preferred over bisphosphonates when creatinine clearance <60 ml/min 7
• Inadequate calcium/vitamin D: Correction of deficiency is essential before and during all antiresorptive therapy 7, 8
• Using raloxifene or romosozumab without considering harms: Raloxifene increases VTE and fatal stroke risk; romosozumab has uncertain cardiovascular harms 3, 2